You are here: Home: LCU 3 | 2006 : Edward S Kim, MD: Select publications

SELECT PUBLICATIONS

Dragnev KH et al. A phase I/II study of bexarotene (B) and erlotinib (E): A novel targeted combination therapy for lung cancer and other aerodigestive tract (ADT) tumors. Proc ASCO 2004;Abstract 3092.

Herbst RS et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23(11):2544-55. Abstract

Kim ES et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: Final report. Proc ASCO 2003;Abstract 2581.

Lee D. Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer. Clin Lung Cancer 2005;7(2):89-91. No abstract available.

Sandler AB et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599. Proc ASCO 2005;Abstract 4.

Table of Contents

Top of Page